<div id="readability-page-1"><p>SG Americas Securities LLC bought a new position in  Astrana Health, Inc. (NASDAQ:ASTH - Free Report) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor  bought 37,460 shares of the company's stock, valued at approximately $1,062,000. SG Americas Securities LLC owned about 0.07% of Astrana Health at the end of the most recent reporting period.</p><div><p><span></span><span>Get <strong>Astrana Health</strong> alerts:</span></p></div><p>Several other institutional investors have also made changes to their positions in ASTH. Royal Bank of Canada increased its holdings in  Astrana Health by 6.5% in the first quarter. Royal Bank of Canada now owns 278,619 shares of the company's stock worth $8,640,000 after buying an additional 17,028 shares during the last quarter.  AQR Capital Management LLC acquired a new position in shares of  Astrana Health during the 1st quarter worth $933,000.  MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of  Astrana Health by 5.2% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,768 shares of the company's stock valued at $799,000 after purchasing an additional 1,263 shares in the last quarter.  Jones Financial Companies Lllp raised its holdings in shares of  Astrana Health by 4,365.2% during the 1st quarter. Jones Financial Companies Lllp now owns 11,163 shares of the company's stock valued at $346,000 after purchasing an additional 10,913 shares in the last quarter.  Finally, Intech Investment Management LLC lifted its stake in shares of  Astrana Health by 5.8% in the 1st quarter. Intech Investment Management LLC now owns 44,586 shares of the company's stock valued at $1,383,000 after purchasing an additional 2,462 shares during the last quarter. 52.77% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Astrana Health Stock Down 1.6%</h2><p>ASTH opened at $26.95 on Monday. The business has a 50 day moving average of $24.00 and a 200-day moving average of $26.88. The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of 141.85, a P/E/G ratio of 0.67 and a beta of 0.87. The company has a current ratio of 1.40, a quick ratio of 1.40 and a debt-to-equity ratio of 1.27. Astrana Health, Inc. has a 1-year low of $20.12 and a 1-year high of $39.97. </p><p>Astrana Health (NASDAQ:ASTH - Get Free Report) last released its earnings results on Thursday, November 6th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.47 by ($0.46). Astrana Health had a net margin of 0.33% and a return on equity of 1.26%. The company had revenue of $956.05 million for the quarter, compared to analyst estimates of $952.83 million. During the same quarter in the previous year, the company earned $0.33 earnings per share. Astrana Health's revenue for the quarter was up 99.7% compared to the same quarter last year.  As a group, sell-side analysts anticipate that  Astrana Health, Inc. will post 1.15 earnings per share for the current year. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Several research firms have weighed in on ASTH. Needham &amp; Company LLC began coverage on Astrana Health in a report on Friday, December 12th. They set a &#34;buy&#34; rating and a $28.00 target price on the stock. Jefferies Financial Group  reissued a &#34;buy&#34; rating on shares of Astrana Health in a research note on Tuesday, November 25th. Weiss Ratings  reaffirmed a &#34;sell (d+)&#34; rating on shares of Astrana Health in a research report on Monday, December 29th. TD Cowen lowered their price target on Astrana Health from $40.00 to $35.00 and set a &#34;buy&#34; rating on the stock in a report on Monday, November 10th. Finally, BTIG Research reduced their price objective on shares of Astrana Health from $50.00 to $45.00 and set a &#34;buy&#34; rating for the company in a research note on Friday, November 7th. Eight investment analysts have rated the stock with a Buy rating, two have assigned  a Hold rating and one  has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Astrana Health presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $41.33.</p><p><b>View Our Latest Stock Analysis on ASTH</b></p><h2>About Astrana Health</h2> (Free Report)<p>Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Astrana Health</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li><li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVNUSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVNUSA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Astrana Health Right Now?</h2><p>Before you consider Astrana Health, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Astrana Health wasn't on the list.</p><p>While Astrana Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ASTH

<p>SG Americas Securities LLC has acquired 37,460 shares of Astrana Health, Inc. (NASDAQ:ASTH) valued at approximately $1,062,000, representing about 0.07% ownership. Other institutional investors have also adjusted their positions in ASTH. The stock is currently down 1.6%, trading at $26.95, with a market cap of $1.52 billion. Astrana Health reported a revenue increase of 99.7% year-over-year, but missed EPS estimates. Analysts have mixed ratings on the stock, with a consensus rating of "Moderate Buy" and a target price of $41.33.</p>

SG Americas Securities LLC Acquires New Shares in Astrana Health, Inc. $ASTH